pubmed-article:7423026 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C0023586 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C0683150 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C0034580 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
pubmed-article:7423026 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
pubmed-article:7423026 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:7423026 | pubmed:dateCreated | 1980-12-16 | lld:pubmed |
pubmed-article:7423026 | pubmed:abstractText | A specific radioimmunoassay (RIA) procedure has been developed for the determination of the narcotic analgesic, levorphanol, in plasma using a rabbit antiserum to an albumin conjugate of (-)-3-hydroxy-N-carboxymethylmorphinan. Assay specificity was achieved by chromatogrphic isolation of levorphanol from plasma extracts on Sephadex LH-20 prior to analysis. The method has a limit of sensitivity of about 0.5 ng/ml of levorphanol using a 0.1 ml sample of plasma. Steady-state plasma concentrations of levorphanol have been determined for the first time in two cancer patients receiving chronic therapeutic doses of the drug. The plasma concentration-time profile for levorphanol following i.v. administration of 2 mg/kg to a dog declined biexponentially and the terminal elimination phase had a half-life of 2.4 hr. When another dog received orally 7 mg/kg of the drug in aqueous solution, the normalized area under the plasma concentration-time curve of intact levorphanol was less than 2% of the are observed after i.v. administration and suggests extensive "first-pass" metabolism of the drug in the dog. | lld:pubmed |
pubmed-article:7423026 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7423026 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7423026 | pubmed:language | eng | lld:pubmed |
pubmed-article:7423026 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7423026 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7423026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7423026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7423026 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7423026 | pubmed:month | Sep | lld:pubmed |
pubmed-article:7423026 | pubmed:issn | 0034-5164 | lld:pubmed |
pubmed-article:7423026 | pubmed:author | pubmed-author:DixonRR | lld:pubmed |
pubmed-article:7423026 | pubmed:author | pubmed-author:FoleyKK | lld:pubmed |
pubmed-article:7423026 | pubmed:author | pubmed-author:CrewsTT | lld:pubmed |
pubmed-article:7423026 | pubmed:author | pubmed-author:InturrisiCC | lld:pubmed |
pubmed-article:7423026 | pubmed:author | pubmed-author:MochacsiEE | lld:pubmed |
pubmed-article:7423026 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7423026 | pubmed:volume | 29 | lld:pubmed |
pubmed-article:7423026 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7423026 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:7423026 | pubmed:pagination | 535-47 | lld:pubmed |
pubmed-article:7423026 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:meshHeading | pubmed-meshheading:7423026-... | lld:pubmed |
pubmed-article:7423026 | pubmed:year | 1980 | lld:pubmed |
pubmed-article:7423026 | pubmed:articleTitle | Levorphanol:radioimmunoassay and plasma concentration profiles in dog and man. | lld:pubmed |
pubmed-article:7423026 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7423026 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |